Baxter International is recalling one lot of 70% Dextrose Injection after stainless steel particles were found in the solution, the third particulate recall to hit a common intravenous product in about a month.
The company issued the announcement Tuesday, and the FDA published it the same day. The affected lot is Y495066, product code 2B0296H, carrying national drug code 0338-0719-06 and an expiration date of July 31, 2027, according to the FDA recall notice. Baxter says it has received no reports of adverse events connected to the issue.
The group with the most direct stake is not hospital inpatients. It is people receiving parenteral nutrition at home, because homecare pharmacies use this product to compound the solutions those patients infuse.
What the Risk Statement Actually Says
The risk language Baxter attached to this recall is unusually direct.
Particulate matter in an intravenous solution can block and clot blood vessels, cut off blood flow to vital organs, lead to a life-threatening pulmonary embolism, and cause permanent organ damage or death, according to the company's notice. The particles can also cause local vein irritation, inflammatory reactions, aggravation of preexisting infections, and allergic reactions.
Baxter has not said whether stainless steel behaves differently in the bloodstream than the fibers and cardboard found in other recent recalls, and the company applied the same general risk category it uses for particulate contamination. What is documented is the composition of what was found and the potential consequences listed above, not a comparative ranking of harm.
The product itself explains where the exposure lands. Seventy percent dextrose is a pharmacy bulk package labeled not for direct infusion. It is a concentrated source of calories that is mixed with amino acids or other compatible fluids to prepare parenteral nutrition for patients who cannot eat or absorb food normally. It reaches a patient only after compounding.
The Nationwide Label Understates How Narrow Distribution Actually Was
One detail in the notice deserves attention because the headline framing obscures it.
Baxter distributed the affected lot to healthcare providers and distributors in select states, naming Alabama, Georgia, and Tennessee. The distribution window ran four days, from July 25 to July 28. So while the recall is administratively nationwide, the product that actually shipped went to a regional footprint over a short period, though the notice says those three states are examples rather than an exhaustive list.
That narrows the practical exposure considerably. A patient on home parenteral nutrition in Ohio or Oregon is unlikely to have received solutions compounded from this lot. Patients in the Southeast whose solutions were compounded in late July or after are the ones with a real question to ask.
Baxter instructed homecare facilities that used the lot to compound parenteral nutrition to contact their patients directly and tell them to stop using those solutions and replace them. That instruction is the operative one for households. The responsibility to reach patients sits with the compounding pharmacy, not with the patient searching a lot number.
Home Parenteral Nutrition Patients Have a Short List of Things to Check
The action here is a phone call, and it should go to the compounding pharmacy rather than to a general provider line.
Patients or caregivers managing home parenteral nutrition can call the pharmacy that prepares their bags, reference the Baxter 70% Dextrose Injection recall and lot Y495066, and ask whether any of their compounded solutions used that lot. Pharmacies track source lots for exactly this reason.
Nobody should discard a supply of nutrition and go without on their own initiative. Parenteral nutrition is not optional for the people who depend on it, and an interrupted supply carries its own risks. The correct sequence is to confirm with the pharmacy and arrange a replacement.
Visual inspection has limits worth stating plainly. Clinicians and caregivers are already trained to inspect solutions for particulates before infusing and to withhold any bag that looks cloudy or contains visible matter. But small fragments may not be visible, which is why lot verification matters more than looking at the bag.
Anyone who has recently received parenteral nutrition and develops sudden shortness of breath, chest pain, or new pain, swelling, redness, or hardness along the infusion vein should seek prompt medical attention. Those signs warrant evaluation regardless of any recall. This is general information and not a diagnosis; no one should change a prescribed nutrition regimen without speaking to their clinician.
Consumers with questions can reach the Baxter Healthcare Center for Service at 888-229-0001 on weekdays between 7 a.m. and 6 p.m. Central Time.
A Third IV Product Recall in Weeks Points at a Pattern Worth Watching
This is not an isolated event in the category. MedicalDaily reported last week on a recalled lot of lactated Ringer's after B. Braun found cotton fibers, wood fibers, and polystyrene inside it, in a voluntary North American recall notice posted by the FDA. Baxter itself recalled a lot of cefazolin in dextrose injection over particulate matter identified as cardboard in late July.
Three particulate recalls in a short span across two manufacturers do not by itself establish a systemic manufacturing problem, and each involved a different product line and a different contaminant. But it does place strain on a category with thin supply margins. Sterile IV solutions have experienced recurring shortages for years, and single-lot withdrawals are absorbed more easily when inventory is healthy.
Several things remain unresolved. The FDA has not yet assigned a recall classification, which is the step that formally rates the health risk and appears in the agency's weekly enforcement reports. Baxter has not disclosed how the stainless steel entered the solution or how many units shipped. Whether the recall expands to additional lots is unknown.
The confirmed facts are narrow. One lot, one four-day distribution window, three named states, no reported adverse events. The households with the most at stake are home parenteral nutrition patients in the Southeast, and their next step is a call to the pharmacy that compounds their bags. The FDA posts classification updates and any expansion through its drug recalls page, and MedicalDaily will report both.
Key Questions Answered
What was recalled? One lot of Baxter 70% Dextrose Injection, USP in a 2000 mL VIAFLEX plastic container, sold as a pharmacy bulk package. Lot Y495066, product code 2B0296H, NDC 0338-0719-06, expiring July 31, 2027.
Why was it recalled? Baxter identified the potential presence of particulate matter in the solution, specifically stainless steel particles.
Where was it distributed? To healthcare providers and distributors in select states, including Alabama, Georgia, and Tennessee, over four days in late July.
Who is most at risk? Patients receiving parenteral nutrition, including at home, since this concentrated dextrose is compounded into those solutions. Home care facilities were instructed to contact affected patients.
Has anyone been harmed? Baxter reported no adverse events connected to the issue as of the announcement date.
What should a home parenteral nutrition patient do? Call the compounding pharmacy, reference the recall and lot number, and ask whether any solutions used that lot. Do not stop nutrition therapy without arranging replacement.
Which symptoms warrant urgent care? Sudden shortness of breath or chest pain after an infusion requires urgent evaluation. New pain, swelling, redness, or hardness along the infusion vein should be reported promptly.
